This Website uses cookies which are essential for providing our services and core website functionality. In addition, if you click on "I AGREE", we will further use analytical and advertising cookies to analyse your use of our Website so that we can improve its functionality and display content tailored according to your interests and preferences, including on third party websites. We use Google Analytics and its tracking and remarketing features connected with Google Ads. This means that cookies on your device will be placed and accessed by Google LLC in the USA enabling us and third parties participating in the Google advertising network to conduct conversion tracking and remarketing activities across different websites and devices. By accepting analytical and advertising cookies you consent to the respective processing and sharing of your personal data with Google LLC. You can withdraw your consent and change your cookie preferences at any time by using our Cookie preferences tool . To refuse consent and continue without analytical and advertising cookies, please click on "I DO NOT AGREE". For more information see our Privacy policy . I agree I do not agree Passion for Innovation. Compassion for Patients.™ Daiichi Sankyo Europe GmbH Countries Services Career Lung Cancer Awareness Month Furthering the Conversation around Biomarker Testing About Us Research & Development Cardiovascular Oncology Media Career suche login Featured Stories Career Would you like to work for Daiichi Sankyo and be an active member of our European family? read more... We Care for Every Heartbeat We are committed to bringing effective cardiovascular therapeutic options and treatment to our patients. read more... Our corporate video provides you with an insight into our company, our Japanese roots, our global history and pathways to innovation and care for patients. Featured News Date Description 11/21/2021 Oncology Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed FLT3-ITD Positive AML PDF 11/18/2021 Oncology TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer PDF 11/03/2021 Oncology Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric Cancer PDF 10/25/2021 Oncology Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer PDF 10/04/2021 Oncology ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens PDF show all About Us Who We Are Daiichi Sankyo in Europe Aspiration and Values European Affiliates European History European Production Sites Global History Responsibility Sustainability Environmental Policy Green Mobility Certificate ISO 14001 CSR in Europe Little Hearts Corporate Conduct Charter Human Rights Policy Business Partner Code of Conduct Patient Groups Sponsoring Transparency Integrity Alert Research & Development Pipeline R&D Network Tissue and Cell Research Center Investigator-Initiated Studies Expanded Access to Investigational Products Cardiovascular Our Commitment We Care for Every Heartbeat Bempedoic Acid Edoxaban Prasugrel Olmesartan CardioXplore CardioConnect Adverse Event Reporting Oncology Daiichi Sankyo Cancer Enterprise Joint Letter on Covid-19 and Cancer Adverse Event Reporting Media European News Events and Congresses Press Contacts Scam Alert Career Your Career at Daiichi Sankyo Europe What it's Like to Work For Us Why Join Us? Spotlight on Our Employees Print page Contact twitter youtube xing linkedin Copyright © Daiichi Sankyo Europe GmbH , all rights reserved. Last update: 25.10.2021 Disclaimer Data Protection Imprint